Common use of Interim Research and Development Reports Clause in Contracts

Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available.

Appears in 25 contracts

Samples: Public Health Service, And Development Agreement, Research and Development Agreement (Ziopharm Oncology Inc)

AutoNDA by SimpleDocs

Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in writing will exchange information and interim progress reports regularly, in writing, on a schedule to be agreed upon by the Parties. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available.

Appears in 4 contracts

Samples: And Development Agreement, And Development Agreement (Globeimmune Inc), And Development Agreement (Globeimmune Inc)

Interim Research and Development Reports. The CRADA PIs Pis should exchange information regularly, in writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available.

Appears in 3 contracts

Samples: Research and Development Agreement (Kite Pharma, Inc.), Research and Development Agreement (Kite Pharma, Inc.), Research and Development Agreement (Kite Pharma, Inc.)

Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become availableavailable these data and documents will be provided in eCTD format, except for IC’s preclinical data that will be provided in standard laboratory data format.

Appears in 1 contract

Samples: Cooperative Research and Development Agreement (Curative Biotechnology Inc)

AutoNDA by SimpleDocs

Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available; these data and documents will be provided in eCTD format.

Appears in 1 contract

Samples: Ziopharm Oncology Inc

Time is Money Join Law Insider Premium to draft better contracts faster.